| Name | Title | Contact Details |
|---|
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Pet First Health Care is a Jeffersonville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gauthier Biomedical is a Grafton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Uprise Health is a company that offers digitally enabled employee assistance programs, mental health services, chronic condition management, and managed behavioral health solutions.
Energist Group is a Nyack, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.